Valuation dashboard for Corcept Therapeutics Incorporated (CORT) with P/E 64.51, P/B 10.48, EV/EBITDA 68.6 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
What would it be worth at its usual multiples?
Versus its usual multiples: expensive · Current P/E 64.5× · Multiples range: $31.17 · $38.98.
At the decade median (24.5×) $31 (-62 %); at its sector median (30.7×) $39 (-52 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
P/E calculated by Kaplio with 12-month GAAP earnings; the data provider reports 54.6×.
Analysis Summary
Corcept Therapeutics Incorporated reported revenue of $761.4M in the most recent fiscal year, growing at a 5-year CAGR of 16.6%. Net income reached $99.7M, with a -1.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 98.5%, operating margin 11.5%, net margin 16.6%.
At $81.93 (closing price, November 3, 2026), CORT trades at a P/E of 64.51 and an ROE of 22.61%. Market capitalisation stands at $8.9B.
Balance sheet quality for CORT: debt-to-equity ratio of 0.01, current ratio of 3.00 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 64.51 |
| Price / Book | 10.48 |
| EV / EBITDA | 68.6 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | $8.9B | 64.51 | 10.48 | 22.6% |
| MBX | MBX Biosciences, Inc. Common Stock | $2.6B | 6.41 | -26.0% | |
| RPRX | Royalty Pharma plc | $29.6B | 38.16 | 4.33 | 12.3% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $12.7B | 165.12 | 12.82 | 8.4% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $7.3B | 71.21 | 10.27 | 17.3% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -2.3% | |
| LQDA | Liquidia Corporation | $3.8B | 30.82 | 19.22 | 149.6% |
| PBH | Prestige Consumer Healthcare Inc. | $2.3B | 13.88 | 1.21 | 9.2% |
Price
| Price | $81.93 (closing price, November 3, 2026) |
| Market Cap | $8.9B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 22.61% |
| Return on Invested Capital | 12.92% |
| Return on Assets | 15.45% |
| Gross Margin | 98.54% |
| Operating Margin | 11.51% |
| Net Margin | 16.57% |
Related companies: MBX · RPRX · 0I3Q.L · KNSA · 0HF9.L · LQDA · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks